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Abstract
In various diseases, such as cancer, autoimmune disease, sepsis
or myocardial infarction, elevated levels of circulating DNA can be
measured. However, its predictive value is under debate.
Circulating DNA in plasma is protein-bound (nucleosomal) DNA.
Quantification of circulating DNA can be performed by real-time
quantitative PCR or immunological methods such as ELISA. The
diagnostic value of both methods can be impaired by inappropriate
handling of the samples. Assessment of circulating DNA in
patients admitted to the intensive care unit offers a tool for
predicting morbidity and mortality.
Introduction
In the previous issue of Critical Care, Rhodes and colleagues
[1] report on significantly increased levels of circulating DNA
in patients admitted to the intensive care unit (ICU) in
comparison with healthy controls. They show plasma DNA
levels to be an independent predictor of mortality and the
development of sepsis in these patients. In sepsis and
trauma, circulating nucleosomal DNA is positively correlated
with disease severity and adverse outcome [2,3]. In cancer,
changes in circulating DNA levels have a prognostic value
[4]. Interestingly, in systemic lupus erythematosus, an
autoimmune disease in which nucleosomal DNA functions as
autoantigenic target, no correlation of circulating nucleosomal
DNA with disease severity can be found; instead there is a
correlation with anti-nucleosomal DNA antibodies [5]. It is
very likely that these antibodies take care of enhanced
clearance of nucleosomes.
Circulating DNA
DNA in plasma most probably circulates bound to proteins in
the form of mononucleosomes and/or oligonucleosomes and
is released after the cleavage of easily accessible linkage
sites of cellular DNA by endonucleases after cell death [6]. A
mononucleosome consists of a core particle composed of an
octamer of two copies each of histones H2A, H2B, H3 and
H4, around which a stretch of helical DNA 146 base pairs in
length is wrapped. Oligonucleosomes are composed of
variable amounts of mononucleosomes connected by intact
linker DNA with a variable length of 15 to 100 base pairs
containing a ‘linker’ histone H1. Once released into the
circulation, nucleosomes seem to be protected by their
structure from further degradation by endonucleases [7].
In healthy individuals, the concentration of circulating DNA is
low, because dead cells are removed efficiently from
circulation by phagocytes. Circulating DNA has a short half-
life (10 to 15 minutes) and is removed mainly by the liver
[8,9]. Accumulation of DNA in the circulation can result from
an excessive release of DNA caused by massive cell death,
inefficient removal of the dead cells or a combination of both.
Rhodes and colleagues demonstrate that increased
circulating DNA not only predicts the development of sepsis
but also mortality in patients admitted to the ICU [1].
Moreover, they show that patients requiring renal support
have significantly higher values of circulating DNA than
patients with sufficient renal function. Unfortunately, the
authors provide no information on liver function, because
most nucleosomal DNA is efficiently cleared by the liver and
only a small fraction is eliminated by the kidney [8,9]. Our
recent study in patients with sepsis showed that nucleosomal
DNA increased with disease severity, but we found no
difference in nucleosome levels in patients with severe renal
insufficiency and normal renal function, respectively [2].
Other studies in patients with trauma and stroke showed that
increased circulating DNA levels were correlated with
morbidity and mortality [3,10]. Hence, assessment of
circulating DNA offers a useful tool for predicting mortality
and morbidity of patients admitted to the ICU. Further studies
on circulating DNA in ICU patients, including more patients
and other scoring systems for illness severity such as SAPS II
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(Simplified Acute Physiology Score II), logistic organ
dysfunction and APACHE II (Acute Physiology and Chronic
Health Evaluation II) scores, are needed to establish
circulating DNA as a predictor for mortality and morbidity in
patients admitted to the ICU.
Assessment of circulating DNA: real-time
PCR versus immunological methods
Quantification of circulating nucleosomes can be assessed
either by real-time quantitative PCR (RQ-PCR) or immuno-
logical assays. The RQ-PCR technique is widely accepted to
quantify circulating DNA in plasma. However, contamination
of a sample with nucleated cells can affect the apparent
concentration of circulating DNA. Sample preparation to
separate plasma from cells is therefore crucial. Chiu and
colleagues [11] showed that a two-step procedure of sample
centrifugation (800g or 1,600g) followed by either high-
speed centrifugation or filtration was superior to a single
centrifugation step only. Nevertheless, a 13.5-fold variation in
circulating DNA levels over 3 days can be detected in female
volunteers [12]. Therefore, even though an appropriate sample
preparation protocol may be used, notable variation requires a
careful interpretation of circulating DNA levels [12].
Nucleosomal DNA can also be assessed by ELISA technique
as recently described by different groups [13,14]. In our
laboratory we developed an ELISA with the use of a mouse
monoclonal anti-histone 3 antibody (CLB-ANA/60) as a
catching antibody and a monoclonal mouse antibody
recognizing an epitope exposed on complexes of histone
H2A, histone H2B and double-stranded DNA, present only
on nucleosomes, as a detection antibody [14]. This technique
renders quantitative determinations reliable and reproducible
[2,13,14]. Also with ELISA, careless blood withdrawal and
delayed centrifugation can result in false positive results, and
insufficient storage conditions can lead to false negative
results [13]. Moreover, sandwich ELISAs are vulnerable to
false positive results resulting from xenoantibodies, C1q,
rheumatoid factors and anti-nucleosome antibodies
(L Aarden, unpublished work).
A comparison of RQ-PCR and ELISA methods revealed a
high concordance in the quantification of circulating DNA in
plasma and serum [15]. Both methods therefore have
applications in measuring circulating DNA. Quantification
should preferably be performed in plasma because, probably
as a result of the clotting process, higher levels of circulating
DNA can be measured [16]. However, determination of
circulating DNA by RQ-PCR seems to be more sensitive than
by ELISA. The lowest circulating DNA level measured by RQ-
PCR in the present study was 14 ng/ml, which corresponds
to 2,121 genome-equivalents/ml (assuming a DNA content of
6.6 pg per cell) [1]. However, circulating DNA can be
detected by RQ-PCR up to 2 genome-equivalents/ml. In our
recent study on nucleosome levels assessed by ELISA, we
reported a detection limit of 35 units/ml, which corresponds
to 3,500 cells/ml [2]. Further improvement of the assay
improved the detection limit to 1,000 cells/ml. Fully
automated systems in DNA isolation, PCR mixture
preparation and rapid thermal cycling profile offer a quick and
sensitive tool for quantifying circulating DNA in plasma.
However, these systems require considerable amounts of
plasma: reliable DNA extraction for RQ-PCR requires at least
200 µl of plasma, whereas only 25 µl suffices for ELISA.
Conclusion
To determine circulating DNA in plasma, appropriate sample
handling is mandatory. RQ-PCR and ELISA techniques have
applications in measuring circulating DNA. Assessment of
circulatory DNA is a useful tool for predicting morbidity and
mortality in patients admitted to the ICU.
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